Greenwich Lifesciences Inc

Company Profile

Greenwich Lifesciences Inc had its IPO on 2020-09-25 under the ticker symbol GLSI.

The company operates in the Healthcare sector and Biotechnology industry. Greenwich Lifesciences Inc has a staff strength of 3 employees.

Stock update

Shares of Greenwich Lifesciences Inc opened at $9.58 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $9.58 - $9.91, and closed at $9.74.

This is a +2.31% increase from the previous day's closing price.

A total volume of 11,733 shares were traded at the close of the day’s session.

In the last one week, shares of Greenwich Lifesciences Inc have increased by +5.53%.

Greenwich Lifesciences Inc's Key Ratios

Greenwich Lifesciences Inc has a market cap of $118.59 million, indicating a price to book ratio of 10.9471 and a price to sales ratio of 0.

In the last 12-months Greenwich Lifesciences Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-9263040. The EBITDA ratio measures Greenwich Lifesciences Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Greenwich Lifesciences Inc’s operating margin was 0% while its return on assets stood at -41.15% with a return of equity of -64.18%.

In Q2, Greenwich Lifesciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Greenwich Lifesciences Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.68 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Greenwich Lifesciences Inc’s profitability.

Greenwich Lifesciences Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -20.3558. Its price to sales ratio in the trailing 12-months stood at 0.

Greenwich Lifesciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$10.95 million

Total Liabilities

$301546.00

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Greenwich Lifesciences Inc ended 2024 with $10.95 million in total assets and $0 in total liabilities. Its intangible assets were valued at $10.95 million while shareholder equity stood at $10.65 million.

Greenwich Lifesciences Inc ended 2024 with $0 in deferred long-term liabilities, $301546.00 in other current liabilities, 12848.00 in common stock, $-45226041.00 in retained earnings and $0 in goodwill. Its cash balance stood at $10.94 million and cash and short-term investments were $10.94 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Greenwich Lifesciences Inc’s total current assets stands at $10.94 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $79618.00 and inventory worth $0.

In 2024, Greenwich Lifesciences Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Greenwich Lifesciences Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$9.74

52-Week High

$21.5

52-Week Low

$8.52

Analyst Target Price

$38

Greenwich Lifesciences Inc stock is currently trading at $9.74 per share. It touched a 52-week high of $21.5 and a 52-week low of $21.5. Analysts tracking the stock have a 12-month average target price of $38.

Its 50-day moving average was $9.53 and 200-day moving average was $12.57 The short ratio stood at 11.33 indicating a short percent outstanding of 0%.

Around 5421.4% of the company’s stock are held by insiders while 646.2% are held by institutions.